A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia

Conditions: Schizophrenia

Interventions: Drug: 30 mg B2227; Drug: 70 mg B2227; Drug: 150 mg B2227; Drug: Vraylar® 1.5 mg; Drug: Vraylar® 3.0 mg; Drug: Vraylar® 4.5 mg; Drug: Vraylar® 6.0 mg

Sponsors: Bostal Drug Delivery Co., Ltd

Not yet recruiting